The raised guidance across total net sales, Opzelura, and Hematology/Oncology signals accelerating commercial momentum beyond Jakafi. Key catalysts ahead include Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa by year-end 2026, and potential U.S. approval for Monjuvi in newly diagnosed DLBCL in Q1 2027. The $1.23B Vega IPRD charge is a one-time non-cash item that does not affect cash flow.
Price Chart
Executive Summary
Incyte reported Q3 2026 total revenue of $1.56B (+14% YoY) and total net sales of $1.32B (+14% YoY), with Jakafi net sales of $827M (+4%), Opzelura net sales of $255M (+36%), and Hematology/Oncology net sales of $235M (+38%). The company raised full-year 2026 total net sales guidance to $5.21B-$5.30B from $5.13B-$5.26B, driven by strong portfolio performance. GAAP net loss was $785M due to a $1.23B IPRD charge from the Vega Therapeutics acquisition, while non-GAAP net loss was $731M.
Key Financial Metrics
Key Facts
- Total revenue of $1.56B in Q3 2026, up 14% YoY
- Total net sales of $1.32B, up 14% YoY
- Jakafi net sales of $827M, up 4% YoY
- Opzelura net sales of $255M, up 36% YoY
- Hematology and Oncology net sales of $235M, up 38% YoY
- Full-year 2026 total net sales guidance raised to $5.21B-$5.30B
- Opzelura net sales guidance raised to $1.10B-$1.12B
- Hematology and Oncology net sales guidance raised to $890M-$910M
- GAAP net loss of $785M driven by $1.23B Vega IPRD charge
- Non-GAAP net loss of $731M
- Cash and marketable securities of $3.9B as of Sept 30, 2026
Financial Impact
Revenue growth of 14% YoY; guidance raised by $80M-$40M at midpoint for total net sales; GAAP net loss of $785M due to one-time $1.23B IPRD charge
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Jakafi | $826.5M | +4.0% |
| Opzelura | $254.9M | +36.0% |
| Hematology and Oncology | $235.0M | +38.0% |
Risk Factors
- Jakafi growth slowing to 4% YoY, with patent cliff beyond 2029
- One-time $246M Opzelura CMS benefit in Q2 2026 creates tough comps for 2027
- GAAP net loss of $785M and non-GAAP net loss of $731M may concern some investors despite being driven by acquisition charges
- Pipeline readouts for INCA033989, latarcibart, and INCB161734 are years away (2027-2029)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000879169-26-000063 |
| Document: incy-20261029.htm | 0000879169-26-000063 |
| Document: 0000879169-26-000063-index-headers.html | 0000879169-26-000063 |
| Document: 0000879169-26-000063-index.html | 0000879169-26-000063 |
| Document: 0000879169-26-000063.txt | 0000879169-26-000063 |
| 8-K Data (Synthetic) | 0000879169-26-000063 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $116.80 | awaiting T+20 | awaiting T+20 | $120.39 (+3.07%) |
Oct 23, 2026 9d ago | Institutional Cluster | $115.71 | awaiting T+20 | awaiting T+20 | $120.39 (+4.04%) |
Aug 14, 2026 11w ago | Insider Cluster | $123.50 $121.74 | ▲ +1.43% | ▼ −0.55% | $120.39 (+2.52%) |
Aug 7, 2026 12w ago | Insider Cluster | $121.55 $124.40 | ▲ +2.34% | ▲ +3.26% | $120.39 (−0.95%) |
Aug 4, 2026 12w ago | Insider Cluster | $119.80 $128.83 | ▲ +7.54% | ▲ +8.14% | $120.39 (+0.49%) |
Jul 28, 2026 13w ago | 8-K | $129.93 $129.72 | ▼ −0.16% | ▼ −3.54% | $120.39 (−7.34%) |
Jul 20, 2026 14w ago | Insider Cluster | $117.39 $123.47 | ▲ +5.18% | ▲ +2.62% | $120.39 (+2.56%) |
Jul 20, 2026 14w ago | Insider Cluster | $117.39 $123.47 | ▲ +5.18% | ▲ +2.62% | $120.39 (+2.56%) |
Jun 8, 2026 20w ago | 8-K | $100.64 $115.62 | ▲ +14.88% | ▲ +13.25% | $120.39 (+19.62%) |
May 27, 2026 22w ago | DEFA14A | $97.26 $108.46 | ▲ +11.52% | ▲ +13.82% | $120.39 (+23.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers